


# Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients

Mao Lin, ... , Lizhi Niu, Yong Jiang

*J Clin Invest.* 2020;130(5):2560-2569. <https://doi.org/10.1172/JCI132712>.

Clinical Medicine Immunology Therapeutics

## Graphical abstract



Find the latest version:

<https://jci.me/132712/pdf>



# Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients

Mao Lin,<sup>1,2</sup> Haihua Luo,<sup>1</sup> Shuzhen Liang,<sup>3</sup> Jibing Chen,<sup>2</sup> Aihua Liu,<sup>4</sup> Lizhi Niu,<sup>2,5</sup> and Yong Jiang<sup>1</sup>

<sup>1</sup>Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failure Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China. <sup>2</sup>Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Guangzhou, China. <sup>3</sup>Medical Research Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. <sup>4</sup>Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. <sup>5</sup>Cancer Center, Fuda Cancer Hospital, Jinan University, Guangzhou, China.

**BACKGROUND.** The anti-programmed cell death 1 (anti-PD-1) antibody pembrolizumab is clinically active against non-small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also express PD-1. This study aimed to investigate the safety and efficacy of pembrolizumab plus allogeneic NK cells in patients with previously treated advanced NSCLC.

**METHODS.** In total, 109 enrolled patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or higher were randomly allocated to group A ( $n = 55$  patients given pembrolizumab plus NK cells) or group B ( $n = 54$  patients given pembrolizumab alone). The patients received i.v. pembrolizumab (10 mg/kg) once every 3 weeks and continued treatment until the occurrence of tumor progression or unacceptable toxicity. The patients in group A continuously received 2 cycles of NK cell therapy as 1 course of treatment.

**RESULTS.** In our study, patients in group A had longer survival than did patients in group B (median overall survival [OS]: 15.5 months vs. 13.3 months; median progression-free survival [PFS]: 6.5 months vs. 4.3 months;  $P < 0.05$ ). In group A patients with a TPS of 50% or higher, the median OS and PFS was significantly longer. Moreover, the patients in group A treated with multiple courses of NK cell infusion had better OS (18.5 months) than did those who received a single course of NK cell infusion (13.5 months).

**CONCLUSION.** Pembrolizumab plus NK cell therapy yielded improved survival benefits in patients with previously treated PD-L1<sup>+</sup> advanced NSCLC.

**TRIAL REGISTRATION.** ClinicalTrials.gov NCT02843204.

**FUNDING.** This work was supported by grants from the National Natural Science Foundation of China (NSFC) – Guangdong Joint Foundation of China (no. U1601225); the NSFC (no. 81671965); the Guangdong Provincial Key Laboratory Construction Project of China (no. 2017B030314034); and the Key Scientific and Technological Program of Guangzhou City (no. 201607020016).

## Introduction

In the past few years, the incidence of lung cancer has increased at a rate of 7.5%, making it the most common malignancy and a serious danger to human health (1, 2). Approximately 80% of lung malignancies are non-small cell lung cancer (NSCLC), which has a 5-year survival rate of only 15% (3). Platinum-based chemotherapy has been the standard-of-care, first-line treatment for advanced NSCLC (2, 4). However, the toxicity and side effects of chemotherapy influence the health and quality of life of patients, and treatment efficacy is limited and appears to have plateaued in the past decade (5, 6). Although treatment for NSCLC has improved with the development of targeted drugs for patients with the corresponding muta-

tions (7, 8), only a small proportion of tumors harbor these mutations, and most tumors become resistant to targeted treatment (9).

Manipulation of the immune system for therapeutic benefit in patients with NSCLC has been studied for decades (10, 11). Immunotherapy targeting the programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitory axis has produced spectacular results in the treatment of a wide variety of tumors (10, 12–15). With the recent development of immune checkpoint inhibitor therapy that blocks the PD-1/PD-L1 pathway, pembrolizumab monotherapy has replaced chemotherapy as the first-line treatment for patients with NSCLC (2, 16), and pembrolizumab plus platinum-based chemotherapy is administered to patients with nonsquamous histology, regardless of their PD-L1 expression status (17).

Natural killer (NK) cells are innate lymphocytes with cytotoxic activity against cancer cells mediated by the release of cytokines and chemokines (18). NK cells participate in immune responses against solid and hematopoietic cancers owing to their capacity to recognize characteristic molecular patterns of stressed cells. Unlike


**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Copyright:** © 2020, American Society for Clinical Investigation.

**Submitted:** August 14, 2019; **Accepted:** January 30, 2020; **Published:** April 13, 2020.

**Reference information:** *J Clin Invest.* 2020;130(5):2560–2569.

<https://doi.org/10.1172/JCI132712>.



**Figure 1. Clinical trial profile and treatment schedule. (A)** Clinical trial profile. In total, 379 patients were selected for enrollment, 249 (65.7%) of whom were assessed for PD-L1 expression. For the 186 (74.7%) PD-L1<sup>+</sup> patients, 78 (31.3%) had PD-L1 expression on at least 50% of their tumor cells. The PD-L1<sup>+</sup> patients were screened for the eligibility criteria, and 109 (58.6%) were enrolled in the study and randomly assigned to group A or B. **(B)** Clinical treatment schedule. Patients in group A received pembrolizumab plus 1-3 courses of allogeneic NK cells; 1 NK cell treatment course was designed to contain 2 cycles, totaling 6 NK cell infusions in 28 days, i.e., days 12, 13, and 14 for the first cycle and days 26, 27, and 28 for the second cycle. Patients in group B received regular therapy with i.v. injection of pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, and the treatment was continued until disease progression or unacceptable toxicity occurred. n = 109.

T cells, NK cells are able to recognize cancer cells without requiring neoantigen or self-antigen overexpression, and loss of MHC expression increases the susceptibility of tumor cells to NK cell-mediated death (19). The killer cell immunoglobulin-like receptors (KIRs) are expressed on the surface of NK cells, and different KIRs recognize and bind different HLA ligands (20). It is advisable to select the KIR and its ligand, HLA class I molecules, from mismatched alloreactive blood donors (21). In our previous studies, allogeneic NK cells achieved a certain inhibitory effect on tumor growth (19, 22). Furthermore, evidence of PD-1 expression on human NK cells has recently emerged in several cancer types (23, 24).

Given the promising results of those studies, we conducted a randomized clinical trial with the aim of investigating the safety and efficacy of pembrolizumab in combination with NK cells as second- or third-line treatment for patients with advanced NSCLC.

**Results**

**Patient enrollment.** Between July 2016 and November 2017, a total of 379 patients were screened for enrollment, 249 (65.7%) of whom were assessed for PD-L1 expression. Of the 186 (74.7%) PD-L1<sup>+</sup> patients, 78 (31.3%) had PD-L1 expression on at least 50% of their tumor cells. The PD-L1<sup>+</sup> patients were screened for the eligibility

**Table 1. Demographic and disease characteristics of the patients at baseline**

	All patients		Patients in group A	
	Group A (n = 55)	Group B (n = 54)	Multiple NK (n = 27)	Single NK (n = 26)
Age (yr)	62.0 (56.0–69.0)	64.0 (58.0–70.0)	60.0 (54.0–68)	63.0 (56.0–69.0)
Male sex	34 (61%)	33 (62%)	16 (60%)	15 (58%)
Smoking status				
Current or former	45 (82%)	44 (81%)	22 (81%)	20 (78%)
Never	10 (18%)	10 (19%)	5 (19%)	6 (22%)
Histology				
Squamous	13 (24%)	12 (22%)	6 (21%)	5 (19%)
Nonsquamous	42 (76%)	42 (77%)	21 (79%)	21 (81%)
PD-L1 TPS				
≥50%	23 (41%)	24 (44%)	12 (44%)	10 (40%)
1%–49%	32 (59%)	30 (56%)	15 (56%)	16 (60%)
EGFR status				
WT	47 (85%)	45 (83%)	23 (86%)	22 (84%)
Mutant	4 (8%)	5 (9%)	2 (6%)	2 (9%)
Unknown	4 (7%)	4 (8%)	2 (8%)	2 (7%)
ALK translocation				
No	48 (88%)	49 (90%)	23 (87%)	22 (86%)
Yes	1 (1%)	1 (1%)	0 (1%)	0 (1%)
Unknown	6 (11%)	4 (9%)	4 (12%)	4 (13%)
Previous therapy				
Adjuvant	3 (5%)	2 (4%)	0 (1%)	1 (2%)
Neoadjuvant	1 (2%)	1 (1%)	1 (2%)	0 (1%)

criteria, and 109 (58.6%) were ultimately enrolled in the study and randomly assigned to group A ( $n = 55$ ) or group B ( $n = 54$ ) (Figure 1A). Baseline characteristics were balanced between the 2 groups (Table 1). The majority of the patients enrolled in the randomized trial were current or former smokers, had tumors with nonsquamous histology, and had previously received first-line systemic treatment. Only a few patients had tumors with an EGFR-sensitizing mutation or anaplastic lymphoma kinase (*ALK*) gene translocation. Baseline characteristics were also similar among the group A patients who received NK cell infusion (Table 1).

**Safety evaluation.** The treatment was well tolerated throughout the trial. Our previous studies confirmed that NK cell infusion had no serious side effects (19, 22), so the adverse events should be attributed to pembrolizumab. The most common adverse events during the trial and the proportions of treatment-related adverse events by grade are shown in Figure 2. There was no significant difference in the incidence of adverse events between the 2 groups ( $P > 0.05$ ). All adverse events were below grade 4, with grade 2 events comprising the majority of events. All symptoms were relieved after symptomatic treatment. No pembrolizumab-related grade 4 adverse events were observed in the patients in this study. Two patients (1.8%) discontinued pembrolizumab treatment.

**Immune parameters.** We evaluated immune parameters and found that there was no significant difference between patients in group A and those in group B before treatment ( $P > 0.05$ ) (Figure 3). After combination treatment, the accumulation of lymphocytes, especially NK cells, significantly increased in group A (Fig-

ure 3A). A representative flow cytometry result for a group A patient is shown in Supplemental Figure 1 (Supplemental material available online with this article; <https://doi.org/10.1172/JCI132712DS1>). Before treatment, the absolute numbers of total T cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and NK cells per microliter were 811.4, 420.1, 315.0, and 66.1, respectively. After combination therapy, the absolute numbers of the same subpopulations of lymphocytes per microliter increased to 1115.7, 569.2, 444.5, and 125.6, respectively. The percentages of total and subtypes of T cells and NK cells are shown in Supplemental Table 1. Notably, NK cells increased from 8.76%  $\pm$  4.06% of the total cell population to 20.67%  $\pm$  5.31% after combination treatment. Interestingly, the levels of Th1 cytokines, including IL-2, TNF- $\beta$ , and IFN- $\gamma$ , increased significantly in group A after treatment (Figure 3B).


**Tumor markers.** We observed no significant differences in the levels of carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (Cyfra21-1), or carbohydrate antigen 125 (CA125) between the 2 groups before treatment, although the levels were above the normal range ( $P > 0.05$ ). Importantly, the levels of CEA, Cyfra21-1, and CA125 in group A were significantly decreased after combina-

tion treatment, despite the fact that some efficacy for pembrolizumab treatment was found in group B (Figure 3C).

**Circulating tumor cells.** We observed no significant difference in the median number of circulating tumor cells (CTCs) between group A and group B before treatment ( $P > 0.05$ ) (Figure 3D). In comparison with the pembrolizumab treatment regimen in group B, the combined treatment regimen in group A showed a more significant effect on the reduction of CTCs in 7.5 mL of blood (13.0  $\pm$  5.3 before treatment to 10.8  $\pm$  3.1 after treatment;  $P < 0.05$ ). A representative flow cytometry result for a group A patient is shown in Supplemental Figure 2.

**Tumor response.** The objective response rate (ORR) was assessed by radiological review and judged according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. The ORR for the total population was 27.5%, and the ORR for group A (36.4%) was superior to that for group B (18.5%) (Table 2). All responses were partial. Representative CT images for 2 patients who received combination therapy are shown in Supplemental Figure 3. The tumor maximum transverse diameters (MTDs) for all patients are shown in Figure 4. Although there was no significant difference in the median tumor MTD between the 2 groups before treatment ( $P > 0.05$ ), it decreased significantly after combination treatment with pembrolizumab plus NK cells ( $P < 0.05$ ).

**Overall survival.** At the time of data cutoff, 86 patients had died, including 38 of 55 (69.1%) patients in group A and 48 of 54 (88.9%) patients in group B. Among the patients with a PD-L1 tumor proportion score (TPS) of 50% or higher, 39 died, including 17 of 23



**Figure 2. All-cause adverse events in the safety population.** (A) All-cause adverse events with a difference of no less than 5% between the study groups. (B) Proportions of patients with treatment-related adverse events presented by grade. There was no significant difference between the 2 groups.  $n = 109$ .  $P > 0.05$ , by  $\chi^2$  test.

(73.9%) in group A and 22 of 24 (91.7%) in group B. The median overall survival (OS) of patients in group A was 15.5 months (Figure 5A), which was longer than that of patients in group B ( $P < 0.05$ ). The benefit of combination therapy received by the patients in group A was consistently observed in all subgroups analyzed (Figure 5B). In the patients with a PD-L1 TPS of 50% or higher, the median OS of patients in group A was 17.0 months, which was longer than that of patients in group B ( $P < 0.05$ ) (Figure 5C). Furthermore, the median OS was significantly longer for patients who received multiple courses of NK cell infusion than for those administered only a single course of NK cell infusion ( $P < 0.05$ ) (Figure 5D).

**Progression-free survival.** Of the 109 enrolled patients, 94 died or had disease progression, i.e., 43 patients from group A and 51 patients from group B died or developed aggravation of their disease. Forty-seven patients had a PD-L1 TPS of 50% or higher, 43 of whom experienced disease progression, including 20 in group A and 23 in group B. The median progression-free survival (PFS) of patients in group A was 6.5 months (Figure 6A), which was superior to that of patients in group B ( $P < 0.05$ ). The benefit of combination therapy received by group A patients was consistently observed in all subgroups analyzed (Figure 6B). The median PFS for group A patients with a PD-L1 TPS of 50% or higher was 7.0 months, which was longer than that for the corresponding group B patients ( $P < 0.05$ ) (Figure 6C). However, we failed to detect a difference in the median PFS between patients who received a single course of NK cell infusion and those who received multiple courses of NK cell infusion ( $P > 0.05$ ) (Figure 6D).


## Discussion

Outcomes are poor for patients with previously treated advanced or metastatic NSCLC, and systemic chemotherapy provides only modest benefits (4). PD-L1 is an immune checkpoint protein

expressed on tumor cells and tumor-infiltrating immune cells that downregulates the antitumor function of T cells through binding to PD-1 (25). Clinical studies of anti-PD-1 antibodies, such as nivolumab and pembrolizumab, have established the therapeutic value of targeting the PD-1/PD-L1 pathway (26, 27). In our study, pembrolizumab was well tolerated with a good safety profile, which is consistent with the results of a previous study by Herbst et al. (14).

PD-1 was reported to be expressed in activated T cells, B cells, NK cells, and NKT cells and plays an important role in regulating the threshold, strength, duration, and properties of antigen-specific immunological responses (28). In the current study, we found that PD-1 was expressed at higher levels in peripheral NK cells and T lymphocytes of patients than in those of healthy donors, which explains the phenomenon that high expression of inhibitory molecules leads to dysfunction and apoptosis of lymphocytes, thereby favoring tumor growth and metastasis. The high PD-1 positivity in patients with cancer was thought to be due to prolonged stimulation by tumor-derived ligands. After blocking the interaction between PD-1 and PD-L1 with pembrolizumab, the phenomenon induced by high PD-1 expression was reversed, and the secretion of IFN- $\gamma$  was increased, which enhanced immune function. Furthermore, PD-1 was expressed at lower levels in patients who received combination therapy, indicating that the combination therapy was more beneficial than pembrolizumab alone, which was explained by the functional recovery of activated NK cells (Supplemental Figure 4). Kamata et al. found that PD-1 expression was elevated in freshly isolated circulating invariant NKT (iNKT) cells from PBMCs of patients with NSCLC and that blockade of PD-L1 augmented Th1 cytokine production in iNKT cells, resulting in cytotoxicity mediated by NK cells (29).





**Figure 3. Evaluation of immune parameters, tumor markers, and CTCs before treatment and 90 days after treatment.** (A) Flow cytometric analysis was performed with 6-Color TBNK Reagent to detect lymphocytes in the blood.  $n = 109$ . Data are shown as box-and-whisker plots (bottom: 25%; top: 75%; line: median; whiskers: minimum to maximum). Comparison within groups:  $*P < 0.05$  and  $**P < 0.01$ , for comparison within groups;  $\#P < 0.05$  and  $\#\#P < 0.01$ , for comparison between groups. Statistical significance was determined by 2-sided Student's  $t$  test. (B) Flow cytometric analysis was performed with the Cytometric Bead Array Human Th1/Th2 Cytokine Kit II to detect cytokines in the blood. (C) The levels of tumor markers including CEA, Cyfra21-1, and CA125 were quantitated by chemiluminescence immunoassay. (D) The number of CD45<sup>+</sup>CK<sup>+</sup>CD326<sup>+</sup> cells (CTCs) was determined with a FACSCanto II. Data are shown as scatter plots with the median and range.  $n = 109$ .  $^{\dagger}P < 0.05$ . ANCOVA was used to analyze the effect of combined treatment on the reduction in CTCs in 7.5 mL of blood compared with pembrolizumab alone.

It is commonly believed that T cells are the only important mediator of the antitumor response unleashed by PD-1 blockade. However, this point of view is challenged by at least 2 observations: (a) PD-1 blockade is still effective in some human tumors with low expression of HLA class I molecules (30), and (b) a strong clinical response to PD-1 blockade is observed in Hodgkin's lymphomas that do not express HLA class I molecules (31). Unlike T cells, NK cells respond to MHC-deficient tumors (32) through activation by ligands whose expression is usually increased upon oncogenic stress (33). On the basis of these premises, we hypothesized that PD-1 blockade might activate NK cell responses.

In this study, human high-activity NK (HANK) cells with activated and cytotoxic status were derived from appropriate allogeneic donors (Supplemental Figure 5). After infusion of the expanded NK cells, the number of NK cells in patients was markedly increased (Supplemental Figure 6), but the patients treated with pembrolizumab alone failed to show any significant effect on the number

of NK cells in the blood, indicating that the NK cell increase in patients was caused by NK cells of donor origin. A previous study by Bouchlaka et al. reported the use nonradioactive isotope fluorine-19 ( $^{19}\text{F}$ ) to label and track NK cells in preclinical models by MRI (34). However, in view of the potential influence on the therapeutic effect and clinical safety, we did not test the presence of NK cells of donor origin with this method. In addition, our result also demonstrated that the expanded NK cells had a stronger cytotoxicity, which was in line with a previous study performed by Kamiya and colleagues (35). Furthermore, we found that combining pembrolizumab with allogeneic NK cell therapy markedly enhanced immune functions, especially cellular immunity, which could be explained by the increased proportion of NK cells in the blood (36). In line with this result, combination therapy also significantly reduced the levels of CTCs and tumor markers. It is well established that a reduction of CTCs reflects the fact that NK cells prevent metastasis and alleviate the residual tumor load by targeting CTCs in the blood (37).

**Table 2. Tumor response**

Response	Total population		Group A		Group B	
	n	Rate, %	n	Rate, %	n	Rate, %
CR	0	0	0	0	0	0
PR	30	27.5	20	36.4	10	18.5 <sup>A</sup>
SD	59	54.1	30	54.5	29	53.7
PD	20	18.3	5	9.1	15	27.8 <sup>A</sup>
ORR	30	27.5	20	36.4	10	18.5 <sup>A</sup>

<sup>A</sup>*P* < 0.05. PD, progression of disease; SD, stable disease.


Garon et al. assessed the efficacy and safety of PD-1 inhibition with pembrolizumab and found that the drug had an acceptable side-effect profile and showed antitumor activity in patients with advanced NSCLC (27). Our study demonstrated that, in comparison with pembrolizumab alone, combined therapy of pembrolizumab plus NK cells had a higher ORR, indicating that combination therapy was superior to pembrolizumab monotherapy. Intriguingly, the combination therapy met the prespecified criteria for improving OS and PFS in all patients, especially those with a TPS of 50% or higher. A survival benefit associated with the combined therapy was also observed in all subgroups. In addition, the patients treated with NK cells had better OS than did those who were never treated with NK cell infusion, and the improvement in OS was associated with the NK cell treatment course, which was consistent with the results of previous studies (22, 25). Notably, less than 10% of the patients enrolled in our trial harbored sensitizing mutations, and treatment with tyrosine kinase inhibitors (TKIs) failed, resulting in tumor progression in these patients. The PFS and OS of patients with sensitizing mutations were 3.1 months and 9.7 months, respectively, results that were much lower than the PFS and OS for the rest of the cohort. However, further studies with a larger patient sample are needed to confirm these results.

This exciting phenomenon confirmed that treatment with pembrolizumab plus NK cells has an enhanced effect in vivo, suggesting that PD-1/PD-L1 blockade elicits an antitumor response by NK cells. This is consistent with the results of previous studies showing that PD-L1 blockade enhances the antitumor efficacy of NK cells (38, 39). Given our results and findings from other studies, it is reasonable to propose that, in addition to T cells, NK cells participate in the clinical benefit of anti-PD-1/PD-L1 antibody therapy by directly killing tumor cells and/or recruiting T cells (39). NK cells have cytotoxic effects against various tumors, but they fail to eliminate tumors completely in vivo, because the high expression of inhibitory molecules (i.e., PD-1) leads to dysfunction and apoptosis of NK cells (29). In addition, several studies have reported that PD-L1 expression in cancer cells results in a reduction of NK cell responses and that PD-1/PD-L1 blockade stimulates NK cell responses in vivo (40, 41), which supports our finding that NK cells combined with a checkpoint inhibitor improved the antitumor effect of NK cells.


Checkpoint inhibitors have revolutionized cancer treatment. Recently, it was reported that PD-1 was expressed on human NK cells in several cancer types, including Hodgkin's lymphoma (23,

24). Several recent mechanistic in vivo studies examined whether and how PD-1 inhibits NK cell responses to tumors and whether PD-1/PD-L1 blockade stimulates NK cell responses. Hsu et al. revealed that PD-1/PD-L1 blockade relieved the inhibition of T cells and NK cells by cancer cells and that combination therapy with antibodies against PD-1 or PD-L1 enhanced the antitumor effects of NK cells (39). Oyer et al. found that combinatorial application of PM21-NK cells and anti-PD-L1 treatment improved NK cell function and significantly extended survival in an animal model of aggressive disseminated peritoneal ovarian cancer (38). Benavente et al. reported that the combination of PD-1 antibody and EGFR blockade in patients with head and neck cancer with high PD-L1 expression improved their clinical response by reversing NK cell dysfunction (41). In addition, Kevin C et al. found that the NK cell/DC axis defined responsive tumor microenvironments in melanoma, which revealed that NK cells, through the production of *FLT3LG* in the tumor, controlled the levels of stimulatory DCs (SDCs) and further improved the responsiveness to anti-PD-1 immunotherapy (42). Dong et al. showed that the binding of anti-PD-L1 monoclonal antibody to PD-L1<sup>+</sup> NK cells induced a strong antitumor activity both in vitro and in vivo, so PD-L1<sup>+</sup> NK cells might be another important immune effector for checkpoint inhibitor-based cancer immunotherapy (40). Andre et al. reported that the immune checkpoint NKG2A/HLA-E was used by cancer cells to evade attack by the immune system and that administration of monalizumab, a humanized antibody against NKG2A, enhanced NK cell activity against various tumor cells and rescued CD8<sup>+</sup> T cell function (43). These various mechanistic studies indicated that immune checkpoint blockade stimulated NK cell responses.

In conclusion, this is the first clinical trial to our knowledge to investigate the safety and efficacy of the combination of pembrolizumab and NK cell infusion. Pembrolizumab combined with NK cells yielded an improved survival benefit in patients with previously treated PD-L1<sup>+</sup> advanced NSCLC. Our results suggest that there are opportunities for the use of anti-PD-1 or anti-PD-L1 antibodies combined with NK cells to enhance antitumor effects (44)



**Figure 4. Effect of combination therapy on tumor MTDs in patients with NSCLC.** Data are shown as scatter plots with the median and range. \**P* < 0.05, compared with before treatment; \*\**P* < 0.05, compared with group B patients. Statistical significance was determined by 2-sided Student's *t* test. *n* = 109.



**Figure 5. OS analysis.** (A) Kaplan-Meier analysis was used to estimate the OS of the total population.  $n = 109$ .  $*P < 0.05$ . (B) Multivariate Cox regression analysis of the OS for key subgroups.  $n = 109$ . (C) Kaplan-Meier analysis was used to estimate the OS of patients with a TPS of 50% or higher.  $n = 47$ .  $*P < 0.05$ . (D) Kaplan-Meier analysis was used to estimate the OS of group A patients who received a single course of NK cell infusion or multiple courses of NK cell infusions.  $n = 53$ .  $*P < 0.05$ .

and offer a potential therapeutic strategy for previously treated patients with PD-L1<sup>+</sup> advanced NSCLC.

## Methods

**Eligibility criteria.** Patients with stage IIIB or stage IV NSCLC, according to the American Joint Committee on Cancer (AJCC) criteria, with documented malignant pleural effusion proven by histology or cytology were enrolled in this study. Other enrollment criteria included the following: measurable disease according to the RECIST guidelines, participants aged 18 years or older, progression after chemotherapy or appropriate TKI treatment for those patients with an EGFR-sensitizing mutation or *ALK* rearrangement, a life expectancy of 3 months or longer, and a PD-L1 TPS of 1% or greater. The most important exclusion criteria were: proven brain metastasis, a history of level 3 hypertension, severe coronary disease, myelosuppression, autoimmune disease, pneumonitis, chronic viral disease, pregnancy, or previous treatment with a therapeutic antibody against CTLA4, PD-L1, or PD-1, or PD-L1/PD-1 pathway-targeting agents.


**Pembrolizumab monotherapy.** Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle. Pembrolizumab treatment was continued as long as the patients received clinical benefit according to investigator assessment (absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results, and clinical status) and the patients consented to continuation.

**HANK cell preparation.** A human HANK Cell In Vitro Preparation Kit (Hank Bioengineering Co.) was used to prepare NK cells with high quantity, purity, and activity from PBMCs. The detailed method for HANK cell expansion and activation is described in Supplemental Methods (see also Supplemental Figure 7 and Supplemental Tables 2 and 3).

**HANK cell cytotoxicity assay.** NK cell viability was assessed by chromium-51 (<sup>51</sup>Cr) release assay as described in the Supplemental Methods.

**Detection of HANK cell-related surface receptors.** The receptors on the cell surface were analyzed with FACS before expansion and 12 days after expansion as detailed in the Supplemental Methods (see also Supplemental Figure 8 and Supplemental Tables 4 and 5).





**Figure 6. PFS analysis.** (A) Kaplan-Meier analysis was used to estimate the PFS of the total population.  $n = 109$ .  $*P < 0.05$ . (B) Multivariate Cox regression analysis of PFS for key subgroups.  $n = 109$ . (C) Kaplan-Meier analysis was used to estimate the PFS of patients with a TPS of 50% or higher.  $n = 47$ .  $*P < 0.05$ . (D) Kaplan-Meier analysis was used to estimate the PFS of group A patients who received a single course of NK cell infusion or multiple courses of NK cell infusion.  $n = 53$ .  $P > 0.05$ .

**Donor selection.** The donors were selected on the basis of genotyping mismatch between the KIR of allogeneic donors and the HLA class I molecules of patients. The detailed method for KIR detection and HLA class I molecule genotyping is described in the Supplemental Methods.

**Treatment procedures.** Using a random number table, patients were divided into group A, which received pembrolizumab plus NK cell therapy, and group B, which was treated with pembrolizumab alone. The treatment schedule is summarized in Figure 1B. Patients in group A received pembrolizumab plus 1 to 3 courses of allogeneic NK cells; 1 NK cell treatment course was designed to contain 2 cycles in a 28-day period, i.e., infusion on days 12, 13, and 14 for the first cycle and days 26, 27, and 28 for the second cycle. The patients in group B received pembrolizumab therapy regularly. Peripheral blood was drawn from a donor for NK cell amplification. Pembrolizumab was administered once every 3 weeks and was continued until disease progression or unacceptable toxicity occurred. Tumors were assessed by CT imaging until disease progression.

**Safety monitoring.** Safety assessments included regular interviews with patients and monitoring of hematological and blood chemistry parameters. Adverse events and complications during treatment were closely observed and recorded. All adverse effects were assessed and reported according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0).

**Detection of PD-1.** Peripheral blood (6 mL) was obtained from healthy donors and patients before treatment and 90 days after treatment for the detection of PD-1. Details can be found in the Supplemental Methods.

**Detection of immune function.** Peripheral blood (2 mL) was obtained from patients before treatment and 90 days after treatment for the detection of immune function by flow cytometry with a FACSCanto II (BD Biosciences). Multitest 6-Color TBNK Reagent and Trucount tubes (337166, BD Biosciences) were used to detect the absolute numbers of CD3<sup>+</sup>CD4<sup>+</sup> cells, CD3<sup>+</sup>CD8<sup>+</sup> cells, total CD3<sup>+</sup> cells, CD3<sup>+</sup>CD19<sup>+</sup> cells, and CD3<sup>+</sup>CD16<sup>+</sup>CD56<sup>+</sup> cells. A human Th1/Th2

Cytokine Kit II (551809, BD Biosciences) for a cytometric bead array was used to detect the expression of IL-2, IL-4, IL-6, IL-10, TNF- $\beta$ , and IFN- $\gamma$ . The tests were carried out according to the manufacturer's protocols. Patients with parameters within the reference range defined by the manufacturer were considered to have normal immune function. Patients with 1 or more parameters with a below-normal value were considered to have immune dysfunction.

**Analysis of CTCs.** Peripheral blood (7.5 mL) was obtained from patients before treatment and 90 days after treatment for the detection of CTCs. The samples were stored at room temperature and processed within 6 hours of collection. Mononuclear cells were separated from other blood components using human PBMC Separation Liquid (LDS1075CB, Tianjin Haoyang Biological Manufacturing Co.). The cells were centrifuged at 1800  $\times$ g for 20 minutes at 4°C and washed twice with sterile HBSS (24020117, Life Technologies, Thermo Fisher Scientific). The isolated cells were enriched by magnetic CD326 (epithelial cell adhesion molecule) MicroBeads (Miltenyi Biotec). Then, a phycoerythrin-labeled (PE-labeled) antibody against CD45 (5B1, 10  $\mu$ L), FITC-labeled antibodies against cytokeratins 8, 18, and 19 (REA885, 10  $\mu$ L), and an allophycocyanin-labeled (APC-labeled) antibody against CD326 (HEA-125, 10  $\mu$ L) (Miltenyi Biotec) were added to the enriched cells, followed by incubation in the dark for 12 minutes at room temperature. The cell pellets were resuspended in 500  $\mu$ L PBS, and the samples were analyzed using a FACSCanto II flow cytometer (BD) with a CD45<sup>-</sup>CK<sup>+</sup>CD326<sup>+</sup> gating strategy. The absolute number of CD45<sup>-</sup>CK<sup>+</sup>CD326<sup>+</sup> cells was used to quantitate the CTC levels.

**Tumor marker detection.** The serum concentrations of CEA, Cyfra21-1, and CA125 were evaluated using a chemiluminescence immunoassay before treatment and 90 days after treatment.

**Tumor response.** The tumor responses of the enrolled patients were assessed by CT in accordance with RECIST, version 1.1. Tumor imaging was scheduled for weeks 6 and 12 and was then performed every 9 weeks through week 48 and every 12 weeks thereafter. Depending on the degree of change in the largest transverse diameter, the therapeutic effect was classified as follows: (a) complete response (CR), in which arterial enhancement imaging showed that all target lesions had disappeared; (b) partial response (PR), in which the total reduction in the diameters of the target lesions was more than 30%; (c) stable disease, in which tumor regression failed to reach the PR definition or tumor progression failed to reach the progressive disease definition; or (d) progressive disease, in which total progression of the tumor was observed, with an increase in the diameter of more than 20%. The curative effect had to be maintained for more than 4 weeks, and a CR plus a PR represents the ORR.

**PFS and OS.** PFS was defined as the interval between treatment initiation and local relapse, distant metastasis, or death, whichever occurred first. OS was calculated as the interval from treatment initiation to death. All patients were consistently monitored after treatment by an intelligent follow-up system (Hospital Information System, version 3.0, Yonyou Medical and Health Information Systems Co. Ltd.), which was complemented with human intervention.

**Statistics.** The primary endpoints were OS and PFS. Safety, immune parameters, CTCs, tumor markers, ORR, and other indexes were the secondary endpoints. The results are presented as the mean  $\pm$  SD or the median  $\pm$  range. A 2-sided Student's *t* test was performed to determine significance when comparing treatment groups, and a *P* value of less than 0.05 was considered statistically significant. To evaluate whether the combined treatment had a more significant effect on the reduction in CTCs, the ANCOVA method was used. Kaplan-Meier analysis was performed to estimate survival and draw survival curves. A stratified log-rank test was performed to assess differences in PFS and OS based on treatment. Stratified Cox proportional hazard models were used to calculate HRs and associated 95% CIs. SPSS, version 22.0 (IBM) was used for statistical analyses.

**Study approval.** This clinical trial was approved by the ethics committee of the Guangzhou Fuda Cancer Hospital, Jinan University (Guangzhou, China). Informed consent was obtained from all 109 patients in accordance with Declaration of Helsinki principles.

## Author contributions

ML contributed to data acquisition, data interpretation, statistical analysis, and drafting of the manuscript. HHL, SL, and JC contributed to data acquisition and statistical analysis. AL, LN and YJ contributed to the study design and critical revision of the manuscript. All the authors had final approval of the submitted manuscript and agreed to be accountable for all aspects of the work.

## Acknowledgments

We sincerely thank Professor Meng Xu (Department of Oncology, First Affiliated Hospital, Jinan University, Guangzhou, China) for providing clinical supervision and data management. We also thank Professor Kecheng Xu (Cancer Center of Guangzhou Fuda Cancer Hospital, Jinan University, Guangzhou, China) for reviewing the manuscript. This work was supported by grants from the NSFC – Guangdong Joint Foundation of China (no. U1601225); the NSFC (no. 81671965); the Guangdong Provincial Key Laboratory Construction Project of China (no. 2017B030314034); and the Key Scientific and Technological Program of Guangzhou City (no. 201607020016).

Address correspondence to: Aihua Liu, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, North Guangzhou Road, Baiyun District, Guangzhou, China. Phone: 86.20.61641575; Email: lah47158@163.com. Or to: Lizhi Niu, Cancer Center, Fuda Cancer Hospital, Jinan University, Tangde Xi Road, Tianhe District, Guangzhou 510665, China. Phone: 86.20.38993994; Email: 18922210657@163.com. Or to: Yong Jiang, Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failure Research, School of Basic Medical Sciences, Southern Medical University, Shatai South Road, Baiyun District, Guangzhou 510515, China. Phone: 86.20.61648231; Email: jiang48231@163.com.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011;61(2):69–90.
2. Zhou Y, et al. Immune-checkpoint inhibitor

plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. *J Immunother Cancer.*

2018;6(1):155.

3. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. *Nat Rev Cancer.*

- 2014;14(8):535–546.
4. Hanna N, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2017;35(30):3484–3515.
  5. Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. *N Engl J Med*. 2005;352(25):2640–2642.
  6. Keller SM, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. *N Engl J Med*. 2000;343(17):1217–1222.
  7. Shaw AT, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*. 2014;370(13):1189–1197.
  8. Jänne PA, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med*. 2015;372(18):1689–1699.
  9. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. *Nat Rev Clin Oncol*. 2014;11(8):473–481.
  10. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443–2454.
  11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674.
  12. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med*. 2012;366(26):2455–2465.
  13. Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med*. 2013;369(2):134–144.
  14. Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*. 2014;515(7528):563–567.
  15. Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature*. 2014;515(7528):558–562.
  16. Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*. 2016;375(19):1823–1833.
  17. Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*. 2018;378(22):2078–2092.
  18. Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. *Science*. 2011;331(6013):44–49.
  19. Lin M, et al. Clinical efficacy of percutaneous cryoablation combined with allogeneic NK cell immunotherapy for advanced non-small cell lung cancer. *Immunol Res*. 2017;65(4):880–887.
  20. Delgado DC, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. *Cancer Res*. 2010;70(23):9554–9561.
  21. Hsu KC, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. *Blood*. 2005;105(12):4878–4884.
  22. Lin M, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. *J Cancer Res Clin Oncol*. 2017;143(12):2607–2618.
  23. Benson DM, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. *Blood*. 2010;116(13):2286–2294.
  24. Liu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. *Oncogene*. 2017;36(44):6143–6153.
  25. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol*. 2008;8(6):467–477.
  26. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*. 2015;373(17):1627–1639.
  27. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372(21):2018–2028.
  28. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. *Nat Immunol*. 2013;14(12):1212–1218.
  29. Kamata T, et al. Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. *Cancer Immunol Immunother*. 2016;65(12):1477–1489.
  30. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. *J Cell Physiol*. 2003;195(3):346–355.
  31. Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*. 2015;372(4):311–319.
  32. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature*. 1986;319(6055):675–678.
  33. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. *Nat Rev Immunol*. 2009;9(8):568–580.
  34. Bouchlaka MN, et al. (19)F-MRI for monitoring human NK cells in vivo. *Oncimmunology*. 2016;5(5):e1143996.
  35. Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. *Cancer Immunol Res*. 2016;4(7):574–581.
  36. Zhang B, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. *Carcinogenesis*. 2007;28(5):1067–1073.
  37. Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. *Immunotherapy*. 2011;3(12):1445–1459.
  38. Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. *Oncimmunology*. 2018;7(11):e1509819.
  39. Hsu J, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. *J Clin Invest*. 2018;128(10):4654–4668.
  40. Dong W, et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. *Cancer Discov*. 2019;9(10):1422–1437.
  41. Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1<sup>+</sup> NK cells in head and neck cancer patients. *Cancer Immunol Res*. 2018;6(12):1548–1560.
  42. Barry KC, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. *Nat Med*. 2018;24(8):1178–1191.
  43. André P, et al. Anti-NKG2A mAb Is a Checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. *Cell*. 2018;175(7):1731–1743.e13.
  44. Mittal D, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. *Cancer Res*. 2014;74(14):3652–3658.